Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Tranexamic Acid
1999783 citationsChristopher J. Dunn, Karen L. GoaDrugsprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
Countries citing papers authored by Christopher J. Dunn
Since
Specialization
Citations
This map shows the geographic impact of Christopher J. Dunn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher J. Dunn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher J. Dunn more than expected).
Fields of papers citing papers by Christopher J. Dunn
This network shows the impact of papers produced by Christopher J. Dunn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher J. Dunn. The network helps show where Christopher J. Dunn may publish in the future.
Co-authorship network of co-authors of Christopher J. Dunn
This figure shows the co-authorship network connecting the top 25 collaborators of Christopher J. Dunn.
A scholar is included among the top collaborators of Christopher J. Dunn based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Christopher J. Dunn. Christopher J. Dunn is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Simpson, Dene, Christopher J. Dunn, Monique P Curran, & Karen L. Goa. (2003). Oxaliplatin. Drugs. 63(19). 2127–2156.52 indexed citations
6.
Scott, Lesley J., Christopher J. Dunn, Gordon Mallarkey, & Miriam Sharpe. (2002). Esomeprazole. Drugs. 62(7). 1091–1118.17 indexed citations
7.
Dunn, Christopher J., Antona J. Wagstaff, Caroline M. Perry, Greg L. Plosker, & Karen L. Goa. (2001). Cyclosporin. Drugs. 61(13). 1957–2016.208 indexed citations
8.
Dooley, Mukta, Caroline M. Spencer, & Christopher J. Dunn. (2001). Aceclofenac. Drugs. 61(9). 1351–1378.93 indexed citations
9.
Dunn, Christopher J. & Karen L. Goa. (2001). Tenecteplase. American Journal of Cardiovascular Drugs. 1(1). 51–66.29 indexed citations
10.
Dunn, Christopher J. & Karen L. Goa. (2001). Risedronate. Drugs. 61(5). 685–712.55 indexed citations
11.
Dunn, Christopher J. & Diana Faulds. (2000). Nateglinide. Drugs. 60(3). 607–615.48 indexed citations
12.
Dunn, Christopher J. & Karen L. Goa. (2000). Lenograstim. Drugs. 59(3). 681–717.33 indexed citations
13.
Dunn, Christopher J. & Caroline M. Spencer. (1999). Recombinant Factor VIIa. BioDrugs. 12(1). 71–77.7 indexed citations
14.
Dunn, Christopher J. & Karen L. Goa. (1999). Tranexamic Acid. Drugs. 57(6). 1005–1032.783 indexed citations breakdown →
15.
Dunn, Christopher J., Andrew P. Lea, & Antona J. Wagstaff. (1997). Carvedilol. Drugs. 54(1). 161–185.80 indexed citations
16.
Dunn, Christopher J. & Anthony Markham. (1996). Epoetin Beta. Drugs. 51(2). 299–318.23 indexed citations
17.
Dunn, Christopher J. & Lee B. Barradell. (1996). Azithromycin. Drugs. 51(3). 483–505.121 indexed citations
18.
Dunn, Christopher J. & Caroline M. Spencer. (1995). Celiprolol. Drugs & Aging. 7(5). 394–411.11 indexed citations
19.
Dunn, Christopher J. & Antona J. Wagstaff. (1995). Epoetin Alfa. Drugs & Aging. 7(2). 131–156.9 indexed citations
20.
Dunn, Christopher J., Andrew Fitton, & Eugene M. Sorkin. (1994). Etidronic Acid. Drugs & Aging. 5(6). 446–474.33 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.